Scholarlink

Purpose of Review <p>This comprehensive review examines nitrosamine impurities, potent carcinogens formed through amine-nitrite reactions, which are predominantly found in pharmaceuticals, food, cosmetics, and environmental sources. Given recent pharmaceutical recalls and growing concerns about developmental toxicity, this review consolidates current knowledge on nitrosamine sources, detection methods, and health effects, with a special focus on at-risk maternal-fetal-infant groups.</p> Recent Findings <p>Recent evidence indicates widespread nitrosamine contamination, resulting in over 1,400 drug recalls for exceeding the acceptable level of 26.5&#xa0;ng/day. The FDA's August 2023 guidelines introduced five potency categories, each with an adequate intake limit ranging from 26.5 to 1,500&#xa0;ng/day. Maternal nitrosamine exposure has been linked to neural tube defects, limb deficiencies, and heart malformations. New electrochemical sensors can now detect levels as low as 1.47&#xa0;nM, although traditional chromatographic methods remain the most common. Nitrosamines can cross the placental barrier, and tobacco-specific nitrosamines (TSNAs) are particularly associated with fetal alcohol spectrum disorder (FASD). Multiple exposure routes during pregnancy include contaminated medications, drinking water (NDMA levels between 2 and 51.8&#xa0;ng/L), processed foods, and secondhand smoke.</p> Summary <p>Nitrosamine exposure is a significant yet modifiable risk factor for adverse developmental outcomes. The review highlights critical knowledge gaps, including human dose-response relationships, long-term developmental effects, and optimal prevention strategies. Recommendations include expanding surveillance of pediatric medications, establishing age-specific exposure limits, promoting maternal education programs, and adopting nitrite-free manufacturing processes. By integrating toxicological, analytical, and public health perspectives, this work presents an evidence-based framework to protect maternal and child health, and underscores urgent research priorities in this evolving field.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nitrosamines in Pharmaceuticals and the Environment: Genotoxic Impurities, Detection Strategies, and Developmental Health Risks

  • 期刊论文

  • 发表日期：

    2026年3月13日

查看全文
  • Uday Shashikumar,
  • Hem Nikhilesh Naik,
  • Jayashree E. Veerabhadra,
  • Vimalkumar Krishnamoorthi,
  • Pei-Chien Tsai,
  • Po-Chin Huang,
  • Yi-Hsun Chen,
  • Smita Jauhari,
  • Yuan-Chung Lin,
  • Vinoth Kumar Ponnusamy,
  • Gopalakrishnan Kumar

摘要

Purpose of Review

This comprehensive review examines nitrosamine impurities, potent carcinogens formed through amine-nitrite reactions, which are predominantly found in pharmaceuticals, food, cosmetics, and environmental sources. Given recent pharmaceutical recalls and growing concerns about developmental toxicity, this review consolidates current knowledge on nitrosamine sources, detection methods, and health effects, with a special focus on at-risk maternal-fetal-infant groups.

Recent Findings

Recent evidence indicates widespread nitrosamine contamination, resulting in over 1,400 drug recalls for exceeding the acceptable level of 26.5 ng/day. The FDA's August 2023 guidelines introduced five potency categories, each with an adequate intake limit ranging from 26.5 to 1,500 ng/day. Maternal nitrosamine exposure has been linked to neural tube defects, limb deficiencies, and heart malformations. New electrochemical sensors can now detect levels as low as 1.47 nM, although traditional chromatographic methods remain the most common. Nitrosamines can cross the placental barrier, and tobacco-specific nitrosamines (TSNAs) are particularly associated with fetal alcohol spectrum disorder (FASD). Multiple exposure routes during pregnancy include contaminated medications, drinking water (NDMA levels between 2 and 51.8 ng/L), processed foods, and secondhand smoke.

Summary

Nitrosamine exposure is a significant yet modifiable risk factor for adverse developmental outcomes. The review highlights critical knowledge gaps, including human dose-response relationships, long-term developmental effects, and optimal prevention strategies. Recommendations include expanding surveillance of pediatric medications, establishing age-specific exposure limits, promoting maternal education programs, and adopting nitrite-free manufacturing processes. By integrating toxicological, analytical, and public health perspectives, this work presents an evidence-based framework to protect maternal and child health, and underscores urgent research priorities in this evolving field.